Potency¶
Quantify how much drug a given effect costs by reading one coordinate off the dose-response curve: the dose that produces half the maximal response (the ED50), so a lower value means less drug suffices.
Core Idea¶
Potency is the pharmacological scalar quantifying how much drug is needed to produce a given effect — specifically the dose producing half the maximal response, the ED50. A drug with a lower ED50 is more potent: less of it achieves the reference effect. Potency is relational, always read at a reference point on the sigmoidal dose-response curve — a coordinate of the drug-receptor-tissue system, not a property of the molecule alone.
Scope of Application¶
Potency is a scalar derived from a dose-response transfer function at a reference operating point, so it applies wherever that precondition holds: a defined sigmoidal dose-response curve with a canonical half-maximal reference effect.
- Clinical and receptor pharmacology — the home: ED50, comparative rankings (morphine ~10x codeine), receptor affinity (Kd) as predictor.
- In vitro screening pharmacology — IC50 for inhibition, EC50 in functional assays.
- Toxicology and risk assessment — LD50 for lethality, carcinogenic-potency dose-per-tumour ranking.
- Endocrinology — hormone potency in receptor binding and downstream cascade activation.
- Pharmacodynamic modelling — fitting the sigmoid so ED50 and ceiling are read as separate coordinates.
Clarity¶
Naming potency makes the loose word "stronger" precise and separates two fused ideas. The critical clarification is that potency is not efficacy: a drug may work at a smaller dose (lower ED50, higher potency) or reach a larger maximum effect (higher ceiling, greater efficacy), and these are independent axes. Holding them apart lets one say morphine is more potent than codeine while both are full agonists capable of the same maximal analgesia.
Manages Complexity¶
Comparing drugs means comparing entire dose-response curves, each with its own slope, midpoint, and plateau. Potency compresses one whole axis to a single coordinate — the ED50, read at a fixed reference point — so "more potent" becomes a checkable, reproducible claim. Held apart from efficacy, it yields two scalars off one sigmoid; drug selection reads off which axis the clinical context makes binding, with receptor affinity predicting the ED50.
Abstract Reasoning¶
Potency licenses diagnostic reasoning (decomposing "stronger" into the ED50 versus ceiling the curve supports, and reading a low ED50 back to tight receptor binding); interventionist reasoning (choosing the lever for whichever axis the context selects, and engineering potency from affinity); and boundary-drawing (potency read only at a specified reference point, on the potency axis alone, never collapsed into a single "strength" ranking).
Knowledge Transfer¶
Wherever its precondition holds — a defined dose-response curve with a canonical half-maximal reference — potency transfers literally across pharmacology and toxicology (ED50, IC50, LD50, hormone potency), carrying its full apparatus. Beyond that, the recurring structural content is leverage — output-per-unit-input around an operating point — carried by the primes leverage, sensitivity, and elasticity (plus ceiling for the efficacy axis). Calling marketing "channel potency" adds no structure; the pharmacological accent (ED50, the sigmoid, receptor affinity) stays home.
Relationships to Other Abstractions¶
Current abstraction Potency Domain-specific
Parents (1) — more general patterns this builds on
-
Potency is a decomposition of Intrinsic Ceiling vs Input Prime
Potency is the pharmacological input-to-approach coordinate, defined by holding that coordinate independent from the response ceiling.
Hierarchy paths (2) — routes to 2 parentless roots
Neighborhood in Abstraction Space¶
Potency sits in a sparse region of the domain-specific corpus (95th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.
Family — Pharmacokinetics & Drug Response (19 abstractions)
Nearest neighbors
- Idiosyncratic Reaction — 0.83
- Partial Agonist — 0.82
- Pharmacodynamic Antagonism — 0.82
- Polypharmacy — 0.80
- Pharmacokinetic Interaction — 0.80
Computed from structural-signature embeddings · 2026-07-12